Scilex Pharmaceuticals Inc. – FDA Inspection, May 20, 2026

Record Details

This FDA Inspection record concerns Scilex Pharmaceuticals Inc., with an inspection on May 20, 2026, issued by the San Francisco District Office, covering human drugs.

Company: Scilex Pharmaceuticals Inc.
Inspection Date: May 20, 2026
Product Type: Human Drugs
Office: San Francisco District Office
Person: Kristin M. Abaonza (FDA Associated Person)

View Company Profile

ID · d7d1ad6c-655c-4bae-bcb9-2ed432935fa4

Inspection Facts

Inspection number: 1318960
FDA center: Human Drugs
Project area: Postmarket Surv. and Epidemiology
Outcome: Form 483 issued

FDA Citations

21 CFR 314.80(b)Failure to develop written procedures

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Scilex Pharmaceuticals Inc.

FDA Inspection

Scilex Pharmaceuticals Inc.May 20, 2026